You just read:

Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

News provided by

Mirati Therapeutics, Inc.

Oct 23, 2019, 16:45 ET